Micrhogam Ultra-filtered Plus

Drug Details

MicRhoGAM Ultra-Filtered Plus is a sterilized solution derived from human blood, designed to prevent an immune response in Rh-negative individuals exposed to Rh-positive blood. This exposure can occur during pregnancy when an Rh-negative mother carries an Rh-positive baby, or through a mismatched blood transfusion. Without intervention, the Rh-negative person's immune system may produce antibodies against Rh-positive red blood cells, potentially leading to complications such as anemia, kidney failure, or shock. Administered via injection, MicRhoGAM Ultra-Filtered Plus helps prevent the formation of these antibodies, thereby reducing the risk of these adverse reactions. It is also used in the treatment of immune thrombocytopenic purpura (ITP), a condition characterized by a low platelet count. Common side effects may include nausea, diarrhea, vomiting, stomach pain, headache, dizziness, drowsiness, weakness, joint or muscle pain, flushing, mild itching or skin rash, increased sweating, or pain or tenderness at the injection site. Severe allergic reactions are rare but can occur; therefore, patients should be monitored for at least 20 minutes after administration. Individuals with a history of severe allergic reactions to human immune globulin products, or those with immune globulin A (IgA) deficiency with antibodies to IgA, should not receive this medication. As with all blood-derived products, there is a minimal risk of transmitting infectious agents, despite rigorous testing and manufacturing processes designed to reduce this risk.